COMBINED HEPATOCELLULAR AND CHOLANGIOCARCINOMA

Clinical trials for COMBINED HEPATOCELLULAR AND CHOLANGIOCARCINOMA explained in plain language.

Never miss a new study

Get alerted when new COMBINED HEPATOCELLULAR AND CHOLANGIOCARCINOMA trials appear

Sign up with your email to follow new studies for COMBINED HEPATOCELLULAR AND CHOLANGIOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

New drug combo trial targets Tough-to-Treat liver cancer

Disease control Not yet recruiting

This study is testing a combination of two immunotherapy drugs (tremelimumab and durvalumab) with two chemotherapy drugs (gemcitabine and cisplatin) for people with an advanced, hard-to-treat form of liver cancer called combined hepatocellular-cholangiocarcinoma (cHCC-CCA). The g…

Matched conditions: COMBINED HEPATOCELLULAR AND CHOLANGIOCARCINOMA

Phase: PHASE2 • Sponsor: Mehmet Akce • Aim: Disease control

Last updated Mar 31, 2026 12:12 UTC

COMBINED HEPATOCELLULAR AND CHOLANGIOCARCINOMA

Get alerted when new COMBINED HEPATOCELLULAR AND CHOLANGIOCARCINOMA trials appear

New drug combo trial targets Tough-to-Treat liver cancer